Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de valores de Sao Paulo  >  Hypermarcas SA    HYPE3   BRHYPEACNOR0

End-of-day quote. End-of-day quote  - 02/24
27.09 BRL   --.--%
02/18 HYPERMARCAS : Material Fact - Guidance
02/16 HYPERMARCAS SA : ex-dividend day for interim dividend
01/03 HYPERMARCAS : Notice to the Market - Drugs Recall
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Hypermarcas SA : Brazil's Hypermarcas returns to profit as debt costs sink

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2012 | 04:03pm CET

Hypermarcas SA, Brazil's largest diversified drugmaker, returned to profit in the third quarter as revenue grew slightly above expectations and debt-servicing and currency hedging costs tumbled from the year-earlier period.

The results were the latest showing that a year-long slowdown in the consumer goods industry is finally easing, with producers of cosmetics, generic drugs and household goods such as Hypermarcas likely to benefit most from Brazil's improving growth trends. Hypermarcas had lost money for two of the past three quarters.

Surging pharmaceutical sales and the integration of acquisitions helped the São Paulo-based producer of Engov hangover pills and Bozzano shaving cream post net income of 68.38 million reais ($33.4 million) in the third quarter, according to a securities filing late on Friday. The result compared with a loss of 190.5 million reais a year earlier.

Third-quarter profit beat the 53 million reais estimate in a Reuters poll of analysts. Management will discuss third-quarter earnings in a conference call with investors early on Monday.

Chief Executive Claudio Bergamo's efforts to streamline operations has restored profitability after a spree of acquisitions in the past four years boosted debt and made Hypermarcas too exposed to an economic slowdown. Bergamo picked pharmaceutical goods and beauty care as the firm's focus, shunning the slower-growing foods and household goods units.

In a separate statement released late on Friday, Management also set an estimate of earnings before interest, tax, depreciation of around 950 million reais for next year, up from guidance of at least 850 million reais in the indicator, known as EBITDA, for this year. EBITDA is a measure of a company's ability to generate profits from its core business.

Lower debt and stronger cash flow generation, coupled with a stable currency, helped Hypermarcas post a net financial shortfall of 54.9 million reais, compared with a deficit of 331.8 million reais a year earlier. The net financial result line is calculated by the difference between debt-servicing and currency hedging expenses and non-operating income, such as gains from financial investments.

Revenue jumped to 992.9 million reais from 832.8 million reais a year earlier, a gain of 19 percent on a year-on-year basis, the company said. Sales of pharmaceutical products, which accounted for about 54 percent of the company's net revenue in the quarter, soared 39 percent, while those of beauty care goods rose 2.2 percent on a year-on-year basis.

The Reuters poll had predicted revenue at 987 million reais for the third quarter.

EBITDA almost quadrupled to 226.6 million reais last quarter from 66.3 million reais in the third quarter of 2011. The EBITDA margin, or how much operating profit was generated from sales, soared to 23 percent from 7.9 percent a year earlier.

EBITDA was expected to come in at 209 million reais in the Reuters poll, below the number reported by the company.

Shares of Hypermarcas, which shed 2.1 percent on Friday and closed the session at 15.32 reais, are up 80 percent so far this year.

($1 = 2.05 Brazilian reais)

(Reporting by Guillermo Parra-Bernal and Vivian Pereira; Editing by Vicki Allen)

By Guillermo Parra-Bernal and Vivian Pereira

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HYPERMARCAS SA
02/18 HYPERMARCAS : Material Fact - Guidance
02/16 HYPERMARCAS SA : ex-dividend day for interim dividend
01/03 HYPERMARCAS : Notice to the Market - Drugs Recall
2016 COTY INC. (NYSE : COTY) Files An 8-K Completion of Acquisition or Disposition of..
2016 HYPERMARCAS : Notice to the Market - Change in Fiscal Council
2016 HYPERMARCAS : Material Fact - Board of Directors and Controlling Group
2016DJCoty Buys Hair Straightener Maker Ghd
2016 HYPERMARCAS SA : ex-dividend day for interim dividend
2016 HYPERMARCAS : Notice to the Market - Audit Committee
2016 HYPERMARCAS : Material Fact
More news
Sector news : Generic Pharmaceuticals
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/24 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
More sector news : Generic Pharmaceuticals
News from SeekingAlpha
2015 Coty acquires Brazilian beauty business
2015 Kimberly-Clark on the hunt for Brazilian diaper business
Advertisement
Financials ( BRL)
Sales 2017 3 626 M
EBIT 2017 1 178 M
Net income 2017 977 M
Finance 2017 2 044 M
Yield 2017 2,85%
P/E ratio 2017 17,48
P/E ratio 2018 15,48
EV / Sales 2017 4,16x
EV / Sales 2018 3,66x
Capitalization 17 127 M
More Financials
Chart HYPERMARCAS SA
Duration : Period :
Hypermarcas SA Technical Analysis Chart | HYPE3 | BRHYPEACNOR0 | 4-Traders
Full-screen chart
Technical analysis trends HYPERMARCAS SA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 30,7  BRL
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Claudio Bergamo dos Santos Chief Executive Officer & Director
João Alves de Queiroz Filho Chairman
Vivian Karina Trujillo Angiolucci Executive Director-Operations
Martim Prado Mattos Chief Financial Officer
Esteban Malpica Fomperosa Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
HYPERMARCAS SA5.68%5 514
OTSUKA HOLDINGS CO LTD1.32%25 658
SUN PHARMACEUTICAL IND..7.06%24 294
ONO PHARMACEUTICAL CO...-1.84%13 192
ASPEN PHARMACARE HOLDI..0.99%10 094
SHANGHAI FOSUN PHARMAC..13.01%9 098
More Results